RMD vs. TAK: A Head-to-Head Stock Comparison

Updated on October 7, 2025

Here’s a clear look at RMD and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

RMD is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	RMD	TAK
Company Name	ResMed Inc.	Takeda Pharmaceutical Company Limited
Country	United States	Japan
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Equipment & Supplies	Pharmaceuticals
Market Capitalization	40.79 billion USD	46.64 billion USD
Exchange	NYSE	NYSE
Listing Date	June 2, 1995	January 5, 2010
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of RMD and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RMD vs. TAK: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	RMD	TAK
5-Day Price Return	2.78%	-0.51%
13-Week Price Return	8.42%	-3.10%
26-Week Price Return	24.45%	-6.75%
52-Week Price Return	16.63%	5.51%
Month-to-Date Return	1.78%	-1.32%
Year-to-Date Return	21.82%	1.84%
10-Day Avg. Volume	0.87M	5.21M
3-Month Avg. Volume	0.93M	4.30M
3-Month Volatility	21.84%	18.77%
Beta	0.88	0.38

Profitability

Return on Equity (TTM)

RMD

25.51%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

In the upper quartile for the Health Care Equipment & Supplies industry, RMD’s Return on Equity of 25.51% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

TAK

1.95%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

TAK’s Return on Equity of 1.95% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

RMD vs. TAK: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

RMD

27.22%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

RMD’s Net Profit Margin of 27.22% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

TAK

3.06%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 3.06% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

RMD vs. TAK: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

RMD

32.75%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

RMD’s Operating Profit Margin of 32.75% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

TAK

8.05%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

TAK’s Operating Profit Margin of 8.05% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

RMD vs. TAK: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	RMD	TAK
Return on Equity (TTM)	25.51%	1.95%
Return on Assets (TTM)	18.61%	0.95%
Net Profit Margin (TTM)	27.22%	3.06%
Operating Profit Margin (TTM)	32.75%	8.05%
Gross Profit Margin (TTM)	59.33%	64.78%

Financial Strength

Current Ratio (MRQ)

RMD

3.44

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

RMD’s Current Ratio of 3.44 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

TAK

1.16

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

TAK’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RMD vs. TAK: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

RMD

0.11

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

Falling into the lower quartile for the Health Care Equipment & Supplies industry, RMD’s Debt-to-Equity Ratio of 0.11 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

TAK

0.66

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

TAK’s Debt-to-Equity Ratio of 0.66 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RMD vs. TAK: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

RMD

661.20

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

With an Interest Coverage Ratio of 661.20, RMD demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.

TAK

1.96

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

RMD vs. TAK: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	RMD	TAK
Current Ratio (MRQ)	3.44	1.16
Quick Ratio (MRQ)	2.16	0.59
Debt-to-Equity Ratio (MRQ)	0.11	0.66
Interest Coverage Ratio (TTM)	661.20	1.96

Growth

Revenue Growth

RMD vs. TAK: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RMD vs. TAK: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RMD

0.76%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

RMD’s Dividend Yield of 0.76% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

TAK

4.55%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

With a Dividend Yield of 4.55%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

RMD vs. TAK: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

RMD

22.19%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

RMD’s Dividend Payout Ratio of 22.19% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

TAK

124.94%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

RMD vs. TAK: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	RMD	TAK
Dividend Yield (TTM)	0.76%	4.55%
Dividend Payout Ratio (TTM)	22.19%	124.94%

Valuation

Price-to-Earnings Ratio (TTM)

RMD

29.18

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

RMD’s P/E Ratio of 29.18 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

TAK

49.74

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

At 49.74, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

RMD vs. TAK: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

RMD

7.94

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

RMD’s P/S Ratio of 7.94 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

TAK

1.52

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.52 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

RMD vs. TAK: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

RMD

6.34

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

RMD’s P/B Ratio of 6.34 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

TAK

1.03

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

TAK’s P/B Ratio of 1.03 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

RMD vs. TAK: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	RMD	TAK
Price-to-Earnings Ratio (TTM)	29.18	49.74
Price-to-Sales Ratio (TTM)	7.94	1.52
Price-to-Book Ratio (MRQ)	6.34	1.03
Price-to-Free Cash Flow Ratio (TTM)	24.76	8.33